Closing the Global Health Gap: Progress Against HIV, TB, and Malaria

By HEOR Staff Writer

August 1, 2023

In the last two decades, the world has seen significant strides in global health, particularly in combating HIV, TB, and malaria. This Oxford study shows that these efforts have not only saved lives but also reduced health inequality and inequity, especially in countries furthest behind.

The article discusses the use of summary indicators of health inequality and inequity to assess improvements in global health outcomes, focusing on HIV, TB, and malaria in fifteen countries in sub-Saharan Africa. The study aims to provide a new perspective on how well health gains benefit countries that are furthest behind in terms of health and economic capacities by using the Gini index and a concentration index ranking countries by gross domestic product (GDP) per capita as indicators of health inequality and inequity.

It was found that from 2002 to 2019, there were significant gains in life expectancy in countries with the lowest life expectancy or low economic development. Inequality in life expectancy across countries declined by one-third during this period, with reduced mortality from HIV, TB, and malaria accounting for half of this gain. The article highlights the importance of considering indicators of health inequality in global health, as it provides valuable insights into health gains.

Reference url

Recent Posts

HIV Treatment Access
Public-Private Partnership Enhances HIV Treatment Access Through Innovative Drug Integration

By João L. Carapinha

June 29, 2026

A new agreement between Merck and the ADAP Crisis Task Force significantly advances HIV Treatment Access by integrating the newly approved single-tablet regimen IDVYNSO™ (doravirine/islatravir) into state AIDS Drug Assistance Programs that served more than 250,000 people with HIV in 2024.
EMA CHMP Meeting Highlights
Regulatory Insights from EMA CHMP Meeting Highlights

By HEOR Staff Writer

June 26, 2026

The EMA CHMP Meeting Highlights from 22-25 June 2026 show the committee advancing six new medicines while maintaining rigorous evidentiary standards for complex and rare conditions. Positive opinions covered an inactivated influenza vaccine for adults 50 and older, a levodopa-carbidopa intestinal...
pharmaceutical innovation benefits
Pharmaceutical Innovation Benefits Driving Socioeconomic Returns in Europe

By João L. Carapinha

June 23, 2026

Pharmaceutical innovation benefits extend well beyond clinical gains, delivering €5.67 in socioeconomic value for every additional euro spent on newer therapies across 29 European countries from 2014 to 2024. By reducing premature mortality, cutting hospital stays, and increasing workforce partic...